24/1, SEVASTOPOLSKY PROSPECT MOSCOW, RUSSIA, 117209


> +7 499 744 66 56 WWW.MCCLINICS.COM





MD MEDICAL GROUP COMPANY PRESENTATION

January 2017



DISCLAIMER

IMPORTANT NOTICE

The information, statements and opinions contained in this presentation do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of any offer to buy any securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.

FORWARD-LOOKING STATEMENTS

This presentation contains forward looking statements, which are based on the Company's current expectations and assumptions and may involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. The forward looking statements contained in this presentation are based on past trends or activities and should not be taken as a representation that such trends or activities will continue in the future. It is believed that the expectations reflected in these statements are reasonable, but they may be affected by a number of variables which could cause actual results or trends to differ materially, including, but not limited to: conditions in the market, market position of the Company, earnings, financial position, cash flows, return on capital and operating margins, anticipated investments and economic conditions; the Company's ability to obtain capital/additional finance; a reduction in demand by customers; an increase in competition; an unexpected decline in revenue or profitability; legislative, fiscal and regulatory developments, including, but not limited to, changes in environmental and health and safety regulations; exchange rate fluctuations; retention of senior management; the maintenance of labour relations; fluctuations in the cost of input costs; and operating and financial restrictions as a result of financing arrangements.

No statement in this presentation is intended to constitute a profit forecast, nor should any statements be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for the Company. Each forward looking statement relates only as of the date of the particular statement. Except as required by the Listing Rules, the Disclosure and Transparency Rules, the Prospectus Rules, the London Stock Exchange or otherwise by law, the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

TEAM PRESENTING TODAY



Dr Mark KurtserCEO, Founder, Controlling shareholder,
Member of the BoD

- Dr Kurtser was a Chief Obstetrician and Gynaecologist of Moscow and Head of the Centre of Family Planning and Reproduction, the largest public obstetrics hospital in Moscow
- Holds a degree in medicine from Pirogov Medical University in addition to a postdoctoral degree in medicine



Elena RomanovaHead of Investor Relations

- Prior to joining MDMG, Elena was IR Senior Manager at Norilsk Nickel. She also worked as an auditor at Ernst & Young and CTC Media
- Holds a degree in Financial Management from Financial University under the Government of the Russian Federation

MD MEDICAL GROUP TODAY

LEADING PRIVATE HEALTHCARE PROVIDER IN RUSSIA

MD Medical Group – #1 private healthcare player in Russia

#1

Largest provider of private healthcare medical services in Russia by revenue¹ with focus on women and children

10 years

Of successful operations on the Russian healthcare market

31 medical facility


- 4 State-of-the-art hospitals providing various world-class services for the entire family
- 27 Industry leading IVF & OBGYN clinics spread throughout Russia

36% / 20%

Average annual revenue / EBITDA growth since 2010

Diversified revenue base

1H 2016



Source: company information

³ Calculated as loans and borrowings - cash and cash equivalents

High quality assets base

	Hospital	Year founded Beds		Area (th. sq.m.)	
	Perinatal Medical Centre (Moscow)	2006	250	28	
	Hospital Lapino (Moscow Region)	2012	182	42	
	Mother and Child Ufa	2014	192	33	
CABULLIA	Mother and Child Novosibirsk	1996 ¹	24	4	

Proven financial performance

RUB mln	2013	2014	2015	1H 2015	1H 2016	
Revenue	5,673	7,201	9,507	4,518	5,814	
growth, y-o-y %	39.7%	26.9%	32.0%	35.7%	28.7%	
EBITDA	1,586	2,083	2,675	1,253	1,657	
EBITDA margin, %	28.0%	28.9%	28.1%	27.7%	28.5%	
Net Income	764	1,320	1,770	768	987	
NI margin, %	13.5%	18.3%	18.6%	17.0%	17.0%	
Net Debt ³	(273)	3,230	1,680	2,096	1,836	
Net Debt / EBITDA	n/a	1.6x	0.6x	0.8x	0.6x	


¹ As of FY2015

² Acquired by Group in 2014




OUR STRENGTHS

OUR STRENGHTS




IMPROVING RUSSIAN ECONOMY...


One of the largest markets globally...




...with stabilizing inflation levels...



...demonstrating firm turnaround trajectory...




...and improving risk profile




Source: Global Insight, Bloomberg consensus, Rosstat

...WITH HIGHLY ATTRACTIVE PRIVATE HEALTHCARE SERVICE MARKET




... and increasing healthcare expenditures...






... resulting in growth of fee-for-service healthcare market...




... with significant room for further upside

Per capita healthcare expenditures1



LEADING PRIVATE HEALTHCARE PLAYER

Private healthcare providers



Sud Zdorov

Focus: General practices

Location: Moscow and Russian regions


Number of clinics: 12

скандинавия. Scandinavia Focus: Women's health, IVF


Location: Saint Petersburg and Russian regions

Number of clinics: 13 (incl. 1 hospital) Number of in-patient beds: 106


Key private market players by revenue (2015)



Key private market players by EBITDA (2015)



UNIQUE CLINICAL CARE OFFERING...



... ON THE BACK OF BEST-IN-CLASS HEALTHCARE FACILITIES THROUGHOUT RUSSIA



Perinatal Medical Centre (Moscow)

27,600 sq m

- Established in 2006, PMC provides a full-range of inpatient and outpatient services to women and children
- The 1st private maternity facility in Moscow and in Russia
- State-of-the-art facility with the latest MRI and CT equipment



Hospital Lapino (Moscow Region)

42,000 sq m

- Company's largest hospital, located in close vicinity to Moscow and established in 2012
- Wide range of obstetrics and gynaecology, IVF, paediatrics, diagnostics, surgery, trauma and rehabilitation services



Mother and Child Ufa

33,000 sq m

- The 1st regional self-constructed hospital of the Group in Russia, established in 2014
- Wide range of in-patient and outpatient services including deliveries, IVF, gynaecology and obstetrics, paediatrics and neonatology
- Services for the whole family. including surgery, urology, plastic surgery and diagnostic services



Mother and Child **Novosibirsk**

 $4,000 \text{ sq } m + 7,000 \text{ sq } m^1$

- Established in 1996 and joined the Group in 2014
- Wide range of in-patient and outpatient services including deliveries, IVF, obstetrics and gynaecology, paediatrics, radiation and ultrasound diagnostic, dentistry and neurosurgery, plastic surgery and urology, traumatology and orthopedics
- New wing of the hospital is expected to be put into operation in Jan-Feb 2017

250 beds

920 FTF

950 FTF

192 beds 400 FTE

1,100

in-patient

days

24 beds

540

deliveries

606 FTF²

3,500 deliveries

290 ths

2,000 IVF

3.000 deliveries

182

beds

1,000 IVF

in-patient

days

3,000 deliveries

IVF 31,0 ths

261 ths

1,800 IVF

treatments

8,0 ths in-patient days

out-patient treatments days

28,5 ths 414 ths in-patient out-patient treatments

19,3 ths

240 ths out-patient treatments

out-patient

Note: FTE = Full-time equivalent, IVF = In-Vitro Fertilisation; All figures represent facilities capacity unless otherwise stated ¹ Upon completion of new hospital wing; ² Actual FTE as of December 2015

HIGH-QUALITY HEALTHCARE INFRASTRUCTURE

Effective equipment management

- Medical equipment provided by highly reputable suppliers, including Siemens, Drager, Storz, Olympus and other industry leaders
- PMC is equipped with high-quality laboratories which conform to the highest international standards
- Comprehensive regular equipment maintenance provided by equipment producers
- Innovative approach with regular implementation of new technologies
 - Continuous monitoring of all new equipment coming to the market
 - o Technical trainings for medical personnel

Blue chip medical equipment suppliers

















Unique and modern equipment

Temporary balloon occlusion of the internal iliac arteries
Cryotop

Allows to avoid complications, preserve reproductive function and decrease the blood loss in OBGYN practice, especially in case of placenta accreta in a Cesarean section scar.



Cryotop method in assisted reproductive treatment

100% survival of embryo High rate of implantation



Dragger Caleo

Unique and new registered method of hypothermia applied for newborns with asphyxia. Let's save lives for newborns who in most cases would die without unique treatment.



MRI Philips Panorama HFO 1.0T Ambient Experience Open aperture of this MRI equipment let's conduct research for patients in critical condition owing to special design, opportunity for a mother to be with a child, safe research for pregnant women and newborns



Integrated operation room OR1™ by KARL STORZ


Best-in-class visualisation during laparoscopic operations. Provides the opportunity for on-line translations and consulting with any specialist all over the world.



PROVEN TRACK RECORD OF SUPERIOR BUSINESS DEVELOPMENT


Introduction of new medical services

 Gradual transition from maternity care focused player to one of the leading multi-disciplinary healthcare provider in Russia through expansion into additional services (cardiology, ophthalmology, traumatology, rehabilitation, etc.) and developing general surgeries at Lapino, Novosibirsk and Ufa hospitals




Expansion in regions

 Company is constantly increasing presence in Russian regions with high disposable income and strong demographic indicators focusing on being the only provider of certain services in a particular region




Building up asset base

- MD Medical Group is focused on increasing its high quality asset base both via organic growth and through execution of accretive M&A deals
- Following measurable approach to expansion, company aims to construct specified number of assets targeting realistic market share in a particular region



OUTSTANDING OPERATIONAL RESULTS





22,351

20,474

18,944

2013

20122011

2010

- 9m'15
 9m'15
 2015
 2014
 8862,825
 2013
 2012
 430,914
 2011
 2010
 299,316
 299,316
 199,207

 CAGR 2012-2015

 43 %
- Track record of a strong growth driven by ramp-up of Lapino & Ufa hospitals, enhanced performance of existing clinics and M&A activity


CAGR 2012-2015

Outstanding growth of IVF partly due to increasing share of state-funded cycles

28,956

• Constantly increasing number of out-patient treatments through launching new departments at Group's hospitals and dedicated out-patient clinics

EXCELLENT FINANCIAL PERFORMANCE



- Top-line performance in line with brokers expectations with actual results exceeding consensus for 2015 at time of IPO
- Strong LfL increase of revenue and EBITDA in 2014-2016 with Lapino hospital being the largest growth contributor
- Stable margins considering increasing number of regional operations with lower prices vs. Moscow offset by increasing share of high-price delivery contracts at Lapino and PMC
- Comfortable level of leverage at 0.6x Net Debt/EBITDA



• Our people are our greatest asset. It is only with the determination and dedication of our people that we can provide best care for our patients


- Based on our commitment to provide best-in-class services and care we see key targets of our HR policy as follows:
 - o retain existing staff and add additional highly skilled employees
 - o invest in the development of our employees
 - o provide an opportunity for personal and career growth
 - o provide our employees with the most advanced technology and equipment
 - o place the best staff in leading positions at the right time to maximize their potential and grow the company from the inside
 - o provide better working conditions to maintain a low staff turnover
 - o develop incentive programs for employees
 - o develop training programs to improve workers' knowledge in various fields

MDMG is proud to provide different means for upgrading professional skills of its employees. In 2016 we continued to improve and diversify the quality of the trainings that we offer to our staff:




OUR PEOPLE ARE OUR GREATEST ASSET

Personnel structure, July 1'16




Payroll structure, July 1'16





Employees, July 1'16




3

STRATEGY



REGIONAL EXPANSION AS ONE OF KEY STRATEGIC TARGETS: MID-TERM PLANS



Key points

- Presence in new regions would be achieved through organic growth and M&A. Company Is constantly monitoring for potential accretive M&A opportunities in several Russian regions
- Top priority for Company's attention would be cities with population over 1 mln people and high level of birth rates & disposable income
- MDMG continues to look for new attractive locations in the cities of its presence, i.e. Moscow, Saint Petersburg

MID-TERM ROLL-OUT PLANS IN RUSSIA

Regional development strategy

- MDMG has a list of targeted regions for mid-term expansion and clear criteria for regions of potential presence:
 - Cities with population over 1 mln people and high level of disposable income
 - High birth rates and/or unsatisfied demand for Company's core services
 - Attractive site location
 - Knowledge of the region
 - Regions without competition are preferred



Overview of short- and midterm development projects

Project		Hospitals				Out-patient clinics			
	Novosibirsk	Samara	Lapino-2	Tyumen	Voronezh	Vladimir	Kemerovo		
CAPEX (RUB min)	1,300	3,000 – 3,500	2,500 + 250 land plot	3,000 – 3,500	80	3.5	50		
Area (sq m)	7,000	15,000	10,000	15,000	400 - 500	80	500		
# of beds	46	147	60	147	-	-	-		
Start of construction / Launch	Nov'15 / Feb'17	Jun'16 / Q1'18	Apr'17 / Nov'18	Q2'17 / H1'18	Feb'17 / Jul'17	Nov'16 /Jan'17	Apr'17 / Sept'17		

4

KEY FINANCIALS

SUMMARY OF OPERATIONAL AND FINANCIAL PERFORMANCE

Key operational and financial indicators

in RUB mln unless otherwise	2013	2014	2015	CAGR,	1H 2015	1H 2016	%
stated	2013	2014	2015	2013-15	IH 2015	10 2016	change
Key operating indicators							
Number of Deliveries	3,816	4,550	5,535	+20%	2,651	3,203	+21%
Number of IVF cycles	5,477	7,654	9,289	+30%	4,211	6,568	+56%
Out-patient visits (admissions), ths.	627	819	1,177	+37%	576	677	+18%
In-patient treatments (patient days), ths.	29	36	51	+33%	26	28	+8%
Key financial indicators							
Revenue	5,673	7,201	9,507	+29%	4,518	5,814	+29%
Gross profit	2,283	2,971	3,589	+25%	1,684	2,222	+32%
EBITDA	1,586	2,083	2,675	+30%	1,253	1,657	+32%
EBITDA margin, %	28%	29%	28%		28%	29%	
Net profit	764	1,320	1,770	+52%	768	987	+28%
Net profit margin, %	13%	18%	19%		17%	17%	
EPS	8.5	15.9	21.4	+59%	9.2	12.0	+31%
DPS	2.4	4.0	6.7	+67%	n/a	3.8	
Dividend payout ratio, %	28%	25%	31%		n/a	32%	
Financial position							
Debt	3,000	4,120	3,454		3,627	3,111	
Cash and cash equivalents	3,273	891	1,774		1,531	1,275	
Net debt ¹	(273)	3,230	1,680		2,096	1,836	
Net debt/EBITDA LTM	(0.2x)	1.6x	0.6x		0.8x	0.6x	
Capex							
Capex (incl. M&A)	3,080	4,931	1,069		343	1,009	

Source: Company data

Comments

Operating indicators

- Strong growth driven by ramp-up of Lapino hospital following its launch in 2012, enhanced performance of existing clinics and M&A activity
 - Utilization rates at Lapino increased to 78% for deliveries and 68% for IVF in 1H 2016 (vs. 58% and 26% respectively in 1H 2014)
 - Increased contribution from Ufa hospital and M&C Novosibirsk starting from 2015

Financial indicators

- Strong LfL increase of revenue and EBITDA in 2014-2016 with Lapino hospital being the largest growth contributor
 - LfL revenue growth of 18% in 2014 and 17% in 2015
 - LfL EBITDA growth of 30% in 2014 and 25% in 2015
- Stable margins despite increasing number of regional operations with lower prices vs. Moscow


Financial position

- Comfortable level of leverage at 0.6x
- The company works with negative working capital as a source of additional financing


¹ Calculated as loans and borrowings - cash and cash equivalents

INVESTMENT PROGRAM

CAPEX structure, incl. M&A



CAPEX dynamics, incl. M&A



Source: Company's audited financial statements under IFRS


Comments

- Group had a solid liquidity position with RUB 1,275mln in cash & cash equivalents as of June 30, 2016
- Group's CAPEX cash outflow (excl. M&A) in 1H
 2016 amounted to RUB 534mIn
 - Ongoing construction of a new wing of hospital in Novosibirsk remained a major contributor to overall CAPEX (estimated put into operations – Jan-Feb 2017)
- On M&A Group spent RUB 475mln in 1H 2016 and RUB 281mln in 2015
 - o Acquisition of ARTMedGroup in 1H 2016
 - Acquisition of Medica Clinic in 2015
- Rationalization of CAPEX spent per new regional facility
 - RUB 3-3.5bn per regional hospital as a benchmark

WORKING CAPITAL

- As company mostly operates on a **pre-payment basis** and the vast majority of revenue comes from direct paying customers, working capital is constantly negative and serves as a **source of additional financing**
- Over the last years company managed to further decrease working capital on the back of efficient payables management and increasing amounts of deferred revenue


Working capital evolution



CONTACTS



24/1, SEVASTOPOLSKY PROSPECT MOSCOW, RUSSIA, 117209 WWW.MCCLINICS.COM



Elena Romanova

Head of Investor Relations

+7 495 331 41 20 e.romanova@mcclinics.ru

Sofia Denisova

IR Manager

+7 495 331 43 57 s.denisova@mcclinics.ru